Hansoh Pharmaceutical Group

Corporate brand

A Chinese pharmaceutical company focused on developing, manufacturing, and selling medicines, with a major presence in psychotropic drugs.

Last updated November 4, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Hansoh Pharmaceutical Group Company Limited is a Chinese pharmaceutical company headquartered in Lianyungang, Jiangsu Province. Founded in 1995 by Zhong Huijuan, the company develops, manufactures, and sells medicines primarily for the mainland Chinese market. Its portfolio spans multiple therapeutic areas, while the company is particularly associated with psychotropic medicines and has been described as China's largest producer of psychotropic drugs. The company was established during the expansion of China's domestic pharmaceutical industry and built its business around the development and commercialization of prescription medicines. Its activities cover pharmaceutical research and development, manufacturing, and sales. Public reference material identifies its products broadly as medicines sold in several categories, but does not provide a complete product-by-product portfolio in the supplied sources. Hansoh is controlled by its founder and her family, who together own approximately 66% of the company according to the referenced Wikipedia material. Zhong Huijuan serves as chair, linking the company's ownership structure with its founding leadership. This concentrated ownership has remained an important characteristic of the business as it developed from a private Chinese drug manufacturer into a publicly traded pharmaceutical group. A major corporate milestone came on 14 June 2019, when Hansoh Pharmaceutical completed an initial public offering on the main board of the Hong Kong Stock Exchange under stock code 3692. The listing gave the company access to public capital markets while retaining its China-centered operating identity. In August 2022, the company was announced as a future addition to the Hang Seng Index, increasing its visibility among Hong Kong-listed companies and investors. Hansoh's brand positioning is that of a large Chinese prescription-drug manufacturer with particular strength in psychotropic medicines. Its business is distinct from a consumer-health or over-the-counter brand: the available reference material presents it as a research, manufacturing, and commercial pharmaceutical group serving medical and therapeutic needs. The company continues to operate as an active business, although the supplied sources do not provide current revenue, workforce, international-market, pipeline, or individual-product details.

History

Hansoh Pharmaceutical Group was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan. The company emerged as part of the growth of China's domestic pharmaceutical sector and developed a business centered on the manufacture and sale of medicines in mainland China. Its activities include pharmaceutical production and commercial distribution, with the available reference material describing a portfolio covering various types of medicine. The company became especially prominent in psychotropic pharmaceuticals. It has been described as China's largest psychotropic drug producer, a distinction that reflects the importance of central-nervous-system and related prescription medicines to its identity. The supplied sources do not list every product or therapeutic franchise, so the company's broader portfolio is best described at the category level rather than through unsupported product claims. Zhong Huijuan has remained closely associated with Hansoh as both founder and chair. The company has a concentrated ownership structure: Zhong and her family are reported to own approximately 66% of the business. This family ownership has continued alongside the company's transition from a privately established pharmaceutical enterprise to a Hong Kong-listed company. Hansoh's most significant capital-markets milestone was its initial public offering on the main board of the Hong Kong Stock Exchange on 14 June 2019. The company trades under stock code 3692. The listing formalized its status as a public pharmaceutical group and expanded the visibility of its business among Hong Kong-market investors. In August 2022, Hansoh was announced as an addition to the Hang Seng Index. Index inclusion represented a further recognition of the company's market presence among Hong Kong-listed businesses. The available materials do not provide details about subsequent index status, changes in ownership, international expansion, research partnerships, product approvals, or financial performance. On the evidence supplied, Hansoh remains an active China-focused pharmaceutical company with particular strength in psychotropic drugs.

2022
Hang Seng Index inclusion announced
[1]Hansoh Pharmaceutical - Wikipediaen.wikipedia.org
The company was announced as an addition to the Hang Seng Index in August 2022.
2019
Hong Kong Stock Exchange listing
[1]Hansoh Pharmaceutical - Wikipediaen.wikipedia.org
Hansoh Pharmaceutical completed its initial public offering on the main board of the Hong Kong Stock Exchange on 14 June 2019 and began trading under stock code 3692.
1995
Company founded
[1]Hansoh Pharmaceutical - Wikipediaen.wikipedia.org
Zhong Huijuan founded Hansoh Pharmaceutical in Lianyungang, Jiangsu Province, China.

Products and positioning

Large Chinese prescription-pharmaceutical group with a leading position in psychotropic medicines.

Prescription pharmaceuticals
Psychotropic medicines
Psychotropic medicines are the most clearly identified product area associated with Hansoh Pharmaceutical. The company has been described as China's largest psychotropic drug producer, making this category central to its corporate positioning. The supplied references do not identify individual brands, active ingredients, indications, or launch dates, so the portfolio is recorded at the therapeutic-category level.
Prescription pharmaceuticals
General pharmaceutical portfolio
Hansoh manufactures and sells various types of medicine in mainland China. The available source material describes the portfolio broadly rather than providing a verified product catalogue. Accordingly, this entry covers the company's wider prescription-pharmaceutical activity without assigning individual products or therapeutic claims that are not documented in the supplied references.

Controversies

2024
Hansoh Pharmaceutical Subsidiary Fined and Confiscated 25.54 Million Yuan for Kickbacks to Doctors via Fake Academic Events
The Enshi City Market Supervision Administration in Hubei found that Jiangsu Hansoh Pharmaceutical, a subsidiary of Hansoh Pharmaceutical, paid a total of 860,200 yuan in service fees to 46 doctors through fake academic activities to promote drugs. Problems included lack of hospital consent, repeated lectures, and forged meeting materials and sign-in sheets. It confiscated illegal gains of 23.4428 million yuan and imposed a fine of 2.1 million yuan, totaling 25.54 million yuan. Media questioned its "kickback-driven sales" model and high sales expenses (totaling 10.5 billion yuan over three years); the company said it was following up internally.
Source

2022
Hang Seng Index inclusionOther
Background
Hansoh's Hong Kong-listed shares had become sufficiently prominent for index consideration.
Action taken
Inclusion in the Hang Seng Index was announced in August 2022.
Aftermath
The announcement increased the company's profile within the Hong Kong equity market. No verified share-price or fund-flow effects are provided in the supplied material.
Source
2019
Initial public offering on the Hong Kong Stock ExchangeOther
Background
Hansoh had developed into a substantial Chinese pharmaceutical manufacturer and pursued a public-market listing.
Action taken
The company conducted an initial public offering and listed on the main board of the Hong Kong Stock Exchange under stock code 3692 on 14 June 2019.
Aftermath
The listing made Hansoh a publicly traded pharmaceutical group in Hong Kong. The supplied sources do not provide verified financial details for the offering.
Source

Recent events

2026.10.19
Reported2026.10.19
Roche acquires rights to Hansoh Pharma ADC portfolio[11]罗氏取得翰森制药抗体药物复合体组合的权利swissinfo.ch
Roche acquired rights to a portfolio of antibody-drug conjugates developed by Hansoh Pharma for $510 million. Hansoh will control early development through completion of the first clinical phase; Roche will then take over globally except in mainland China, Hong Kong, Macao and Taiwan.
2026.10.19
Reported2026.10.19
Hansoh Pharma and Roche announce ADC collaboration[12]翰森制药与罗氏宣布ADC合作prnasia.com
Hansoh Pharma announced a strategic collaboration and licensing agreement with Roche for new antibody-drug conjugate projects. Hansoh will lead early development through completion of global Phase Ia trials and retains development, registration and commercialization rights in mainland China, Hong Kong, Macau and Taiwan; Roche will lead further development elsewhere.
2021.06.17
Reported2021.06.17
Blossom Biosciences completes $72 million Series A financing[13]博胜药业完成7200万美元A轮融资finance.sina.com.cn
Blossom Biosciences announced that it had completed a $72 million Series A financing led jointly by Hansoh Pharma and Cormorant Asset Management.
2021.06.17
Reported2021.06.17
Hansoh Pharma agrees to support Blossom Biosciences[13]博胜药业完成7200万美元A轮融资finance.sina.com.cn
Hansoh Pharma and Blossom Biosciences reached an agreement for Hansoh to provide preclinical, clinical and commercialization support to accelerate development and launch of Blossom's pipeline in China.
2020.03.30
Reported2020.03.30
Hansoh Pharmaceutical releases 2019 results[14]翰森制药发布2019年业绩报告finance.sina.com.cn
Hansoh Pharmaceutical released its 2019 results, reporting revenue of approximately RMB 8.683 billion and profit of approximately RMB 2.557 billion.

Sources15 sources

Cite this profile: Cite the canonical profile. /brand-wiki/hansoh-pharmaceutical-group · Editorial policy · How profiles are compiled